Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
15.84
+0.11 (0.70%)
At close: May 28, 2025, 4:00 PM
16.30
+0.46 (2.90%)
After-hours: May 28, 2025, 6:16 PM EDT
Mineralys Therapeutics Employees
Mineralys Therapeutics had 51 employees as of December 31, 2024. The number of employees increased by 23 or 82.14% compared to the previous year.
Employees
51
Change (1Y)
23
Growth (1Y)
82.14%
Revenue / Employee
n/a
Profits / Employee
-$3,696,333
Market Cap
1.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51 | 23 | 82.14% |
| Dec 31, 2023 | 28 | 16 | 133.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MLYS News
- 4 days ago - Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - GlobeNewsWire
- 8 days ago - Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - GlobeNewsWire
- 15 days ago - Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 16 days ago - Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference - GlobeNewsWire
- 23 days ago - Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - GlobeNewsWire
- 5 weeks ago - Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - GlobeNewsWire
- 2 months ago - Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - GlobeNewsWire